Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

*仅供医学专业人士阅读参考说到“免疫治疗进展有限”的常见癌症，大家的第一反应会是什么？如果回答是肠癌、胰腺癌、卵巢癌那当然都算正解，但奇点糕要补充一个可能常常被忽略的存在——乳腺癌：虽说在HER2阳性和三阴性乳腺癌治疗中，免疫治疗确实有着不错的效果， ...

【导读】激素受体阳性（HR+）/人表皮生长因子受体2阴性（HER2-）乳腺癌是最常见的乳腺癌类型，持续复发仍是一个重要的临床问题。目前针对HR+/HER2-乳腺癌患者的复发预测模型仍存在局限性。整合多维数据是预测复发的一种有前途的替代方法。2025年 ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...